Effects of complexation with in vivo enhancing monoclonal antibodies on activity of growth hormone in two responsive cell culture systems.
We describe the properties of three monoclonal antibodies (MAbs) to ovine GH, two of which have previously been shown to enhance, in vivo, the biological activity of bovine and ovine growth hormone. We have examined the effects of these MAbs on GH activity in two appropriate GH-responsive cell culture systems, investigating both acute signalling effects (Janus-activated kinase (Jak)-2 tyrosine phosphorylation -5 min) and longer-term (MTT-formazan production -24 h) effects of hormone-antibody complexes. In the 3T3-F442A pre-adipocyte cell line (which has been demonstrated to be GH responsive), we show that complexation of recombinant bovine (rb) GH with either of the two enhancing anti-ovine GH MAbs (OA11 and OA15) and the non-enhancing MAb, OA14, attenuates the ability of GH to stimulate tyrosine phosphorylation of Jak-2 at a 5-min time point. Using the mouse myeloid cell line, FDC-P1, stably transfected with the full-length ovine GH receptor (oGHR), we demonstrate that rbGH causes a dose-dependent increase in MTT-formazan production by these cells. Further, we demonstrate that OA11 and OA14, but not OA15, cause a decrease in this stimulatory activity of rbGH over a hormone concentration range of 5-50 ng/ml at both 24 and 48 h. We conclude that the different in vitro activities of the two in vivo enhancing MAbs are most probably related to the time-courses over which these two assays are performed, and also to the relative affinities between antibody, hormone and receptor. In addition, the in vitro inhibitory activity of the enhancing MAb OA11 in both short- and long-term bioassay lends further support to an exclusively in vivo model for MAb-mediated enhancement of GH action.
Beattie
J
J
Hannah Research Institute, Ayr KA6 5HL, UK. beattiej@hri.sari.ac.uk
Borromeo
V
V
Bramani
S
S
Secchi
C
C
Baumbach
W R
WR
Mockridge
J
J
D017667:Adipocytes / Q000166:cytology / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D000936:Antigen-Antibody Complex / Q000276:immunology / Q000494:pharmacology*; D001665:Binding Sites; D002417:Cattle; D002460:Cell Line; D005562:Formazans / Q000378:metabolism; D013006:Growth Hormone / Q000819:agonists* / Q000037:antagonists & inhibitors / Q000276:immunology / Q000494:pharmacology*; D053614:Janus Kinase 2; D051379:Mice; D010766:Phosphorylation / Q000187:drug effects; D019000:Phosphotyrosine / Q000378:metabolism; D011388:Prolactin / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011518:Proto-Oncogene Proteins; D051381:Rats; D011986:Receptors, Somatotropin / Q000235:genetics / Q000378:metabolism; D012756:Sheep; D015398:Signal Transduction / Q000187:drug effects*; D013379:Substrate Specificity; D013778:Tetrazolium Salts / Q000378:metabolism; D013997:Time Factors; D014162:Transfection
D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D005562:Formazans; D011518:Proto-Oncogene Proteins; D011986:Receptors, Somatotropin; D013778:Tetrazolium Salts; D019000:Phosphotyrosine; C079782:MTT formazan; D011388:Prolactin; D013006:Growth Hormone; D011505:Protein-Tyrosine Kinases; C507926:Jak2 protein, mouse; C507927:Jak2 protein, rat; D053614:Janus Kinase 2